Unique risk factors for bacteraemia in allogeneic bone marrow transplant recipients before and after engraftment

Bone Marrow Transplantation
K Y YuenR Liang

Abstract

A study of the risk factors associated with bacteraemia in 191 allogeneic bone marrow transplant (BMT) recipients (1991-1996) was performed. In contrast to risk factors commonly cited for cancer chemotherapy, mucositis, degree of conditioning toxicity of the gut and lungs, duration of neutropenia, and severity of neutropenia and monocytopenia were not associated with bacteraemia in the pre-engraftment period, during which the only significant risk factor was late stage underlying disease (P < 0.05). After engraftment, Hickman catheter infection, and severe acute and chronic graft-versus-host disease (GVHD) were found to be independently associated with bacteraemia by multivariate analysis (P < 0.001, <0.05 and <0.05, respectively). This might be explained by intense antimicrobial prophylaxis, early empirical treatment, and non-routine use of haemopoietic growth factors. No significant difference in mortality was detected between bacteraemic and non-bacteraemic patients in both periods. Allogeneic BMT recipients are therefore a group of patients distinct from other cancer patients receiving chemotherapy at risk of developing bacteraemia. The study findings prompt consideration of a management protocol incorporating early and rou...Continue Reading

Citations

Jul 12, 2002·Hematological Oncology·K Y Yuen, P C Y Woo
Sep 22, 2012·Journal of Pediatric Hematology/oncology·Takeo SarashinaRyoji Kobayashi
Aug 29, 2003·Journal of Clinical Pathology·P C Y WooK Y Yuen
Sep 27, 2003·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Hideki MitsuiAkira Hiraoka
Sep 30, 2015·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Kazuaki KamedaYoshinobu Kanda
Dec 3, 2008·Blood Reviews·Leon J Worth, Monica A Slavin
Dec 14, 2004·Pediatric Blood & Cancer·Leslie S KersunAngela Demichele
Apr 27, 2004·Cancer·Stephen T SonisUNKNOWN International Society for Oral Oncology
Jan 13, 2015·Transplant Infectious Disease : an Official Journal of the Transplantation Society·M KikuchiY Kanda
Oct 3, 2008·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·P C Y WooK-Y Yuen
Dec 7, 2013·Experimental Biology and Medicine·Peter L PontoppidanPer T Sangild
Jan 18, 2005·The Journal of International Medical Research·M E OnwuamaegbuC Soare
Jul 17, 2012·Journal of Pediatric Oncology Nursing : Official Journal of the Association of Pediatric Oncology Nurses·Medine C YilmazBengu Demirag
Jul 23, 2008·The Cochrane Database of Systematic Reviews·Susanne QuellmannJulia Bohlius
Nov 6, 2001·Journal of the National Cancer Institute. Monographs·S A Khan, J R Wingard
May 13, 2018·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Marissa K McDonaldGowri Satyanarayana
Jun 18, 2018·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Yasuo MoriToshihiro Miyamoto

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.